Riborea 500mg Capsule

About

Riborea 500mg Capsule contains Ribociclib, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor. This medication is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Ribociclib works by selectively inhibiting CDK4 and CDK6, which are key regulators of cell cycle progression. By blocking these kinases, Ribociclib arrests cancer cells in the G1 phase of the cell cycle, preventing their proliferation and tumor growth. It is typically used in combination with an aromatase inhibitor or fulvestrant as endocrine-based therapy.

This targeted approach significantly improves progression-free survival in eligible patients, offering a crucial advancement in the management of this specific subtype of breast cancer. Regular monitoring for potential side effects, particularly neutropenia and liver enzyme elevations, is important during treatment.

Uses

• HR-positive, HER2-negative advanced breast cancer
• Metastatic breast cancer (HR+, HER2-)
• First-line treatment for postmenopausal women
• Treatment for pre/perimenopausal women (with LHRH agonist)

Directions For Use

Take orally once daily for 21 consecutive days, followed by 7 days off, to complete a 28-day cycle. Take with or without food.

Benefits

• Effective in HR+, HER2- advanced breast cancer.
• Oral administration offers convenience.
• Significantly improves progression-free survival.
• Targeted therapy with a specific mechanism.
• Can be used in combination with endocrine therapy.
• Offers a new treatment option for this patient population.

Side Effects

• Neutropenia (common and potentially severe)
• Nausea
• Fatigue
• Diarrhea
• Alopecia
• Vomiting
• Headache
• Constipation
• Rash
• Elevated liver enzymes (ALT/AST)
• Prolonged QT interval
• Infections

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may exacerbate gastrointestinal side effects or liver strain. Use in moderation.
• Pregnancy - Contraindicated. Ribociclib can cause fetal harm. Use effective contraception during treatment and for at least 3 weeks after the last dose.
• Breastfeeding - Contraindicated. It is unknown if ribociclib is excreted in human milk; discontinue breastfeeding due to potential for serious adverse reactions.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments are necessary; monitor liver function tests closely.
• Kidney - Use with caution in patients with severe renal impairment. Dose adjustments may be necessary; monitor renal function closely.
• Lung - Monitor for new or worsening respiratory symptoms, as interstitial lung disease/pneumonitis has been reported.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.